« Back to Record
Citation APA

Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G. E., Saussez, S., & Journé, F. (2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer cell international, 24(1), 8. doi:10.1186/s12935-023-03196-y


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/371346

Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G. E., Saussez, S., & Journé, F. (2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer cell international, 24(1), 8. doi:10.1186/s12935-023-03196-y